Medical Marijuana … and no growing??? InMed Pharmaceuticals (OTC: IMLFF), a pre-clinical stage biopharmaceutical company that has increased 180% over the past year and is “more than just another cannabis drug company,” according to a new Forbes article, is inviting you to take a look at their proprietary biosynthesis process for manufacturing all 90-plus naturally occurring cannabinoids — all without growing any plants!
Recently the company was featured in a Forbes article where the top business magazine highlighted InMed for “making the right moves to build its reputation and create revenue sources besides a drug pipeline,” including developing a proprietary cannabinoid manufacturing system, as well as a highly sought-after database that maps different compounds of cannabinoids to the various diseases they can address. This database, which according to Forbes, “has become a core asset” for InMed, was initially created to help the Company in its research, but now other biotech companies are willing to pay for this mapping information.
Cannabis contains over 90 cannabinoids, some of which have been found to have therapeutically beneficial properties. However, unlike medical marijuana processors that mainly use the two major cannabinoids — cannabidiol (CBD) and tetrahydrocannabinol (THC) – because they are easy to extract in a large volume from the plant, InMed uses a bioinformatics algorithm to screen the over 90-plus cannabinoid structures against approved drugs, diseases and genetic profiles of diseases. The Company’s system then selects specific cannabinoids that might help regulate a particular disease.
This is an algorithm to assess the different cannabinoids in the plant and screen them against:
- Approved drug structures,
- Disease site receptors
- Genetic profiles of diseases
- The involvement of proteins and chemical metabolites in disease pathways
This program then selects specific cannabinoids, or combinations thereof, that might play a role in regulating diseases. This can help:
- Generate new therapies quickly and effectively
- Allow InMed to research pharmacological responses of all 90-plus cannabinoids
This tool is saving time and money in the drug research process and has helped InMed to identify therapies for conditions like a rare children’s skin disease called epidermolysis bullosa (EB) and glaucoma.
The Company plans to start clinical trials in 2018 for the EB drug and the glaucoma drug, which Forbes estimates would have a potential market size of about $1 billion a year and $6 billion a year respectively.
The Forbes article also suggested that InMed is unique for a biotech company because it offers more than just a drug pipeline, such as its database and is also a unique method of biosynthesis for cannabinoids.
Biosynthesis allows InMed to provide a biologically identical cannabinoid that can then be used in pharmaceuticals for use to treat multiple ailments and conditions. Additionally, this process can allow the company to not only look at the common cannabinoids like CBD and THC, but also minor cannabinoids that have been economically unfeasible to develop into drugs to this point.
The process also provides multiple benefits when it comes to cost saving, time restrictions and other resources. For instance:
- Reduced cost on resources to extract and purify product from the plants
- Reduced electricity and water costs
- No need to wait the 12-14 weeks for a crop to grow
- Or with Synthetic cannabinoids not having to wait the 10 weeks it takes to create them
- Crops vary depending on environment and are difficult to have standardized
- Synthetic cannabinoids create waste, are similar but not the same and generally come with side effects
This less expensive, more scalable biosynthesis method is similar to the one used to create synthetic insulin for millions of diabetic patients and gives access to minor cannabinoids that are currently not economically capitalized upon to develop into drugs.